Kymera Therapeutics Inc. (KYMR)
Market Closed
1 Sep, 20:00
NASDAQ (NMS) NASDAQ (NMS) Primary 
XKLS $
119. 05
+0.24
+0.202%
$
9.77B Market Cap
- P/E Ratio
- Div Yield
576,564 Volume
-2.54 Eps
$ 118.81
Previous Close 
Want to track KYMR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Why Kymera Therapeutics Stock Is Soaring Today
Sanofi plans to expand phase 2 clinical studies evaluating Kymera's KT-474. This move could accelerate pivotal testing for the potential skin treatment.
Fool | 2 years ago
Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies
Kymera (KYMR) announces expansion plans of ongoing mid-stage studies on KT-474 (SAR444656) by partner Sanofi.
Zacks | 2 years ago
